NCT03136146
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +29 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Explore clinical trials studying Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements. Study availability and eligibility vary by location and protocol.
9 public trials
5 recruiting studies
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements trial results
NCT06649812
- Conditions
- Hemic and Lymphatic Diseases, High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Immune System Diseases, +23 more
- Locations
-
- Banner University Medical Center - Tucson Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
- Cedars-Sinai Medical Center Los Angeles, California, United States
- Smilow Cancer Hospital-Derby Care Center Derby, Connecticut, United States
NCT06536049
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +22 more
- Locations
-
- University of Minnesota/Masonic Cancer Center Minneapolis, Minnesota, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
NCT07042438
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
NCT05755087
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, +6 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, not recruiting
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
NCT05821088
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +30 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, not recruiting
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
NCT03038672
- Conditions
- ALK-Positive Large B-Cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +53 more
- Locations
-
- Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
- Mayo Clinic in Arizona Scottsdale, Arizona, United States
- Mayo Clinic in Florida Jacksonville, Florida, United States
- Moffitt Cancer Center-International Plaza Tampa, Florida, United States
Active, not recruiting
TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT05507541
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +36 more
- Locations
-
- University of Iowa Iowa City, Iowa, United States
- Mayo Clinic Rochester, Minnesota, United States
Completed
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas
NCT01897012
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +36 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States